An adaptive neuro-fuzzy propagation model for LoRaWAN

This article proposes an adaptive-network-based fuzzy inference system (ANFIS) model for accurate estimation of signal propagation using LoRaWAN. By using ANFIS, the basic knowledge of propagation is embedded into the proposed model. This reduces the training complexity of artificial neural network (ANN)-based models. Therefore, the size of the training dataset is reduced by 70% compared to an ANN model. The proposed model consists of an efficient clustering method to identify the optimum number of the fuzzy nodes to avoid overfitting, and a hybrid training algorithm to train and optimize the ANFIS parameters. Finally, the proposed model is benchmarked with extensive practical data, where superior accuracy is achieved compared to deterministic models, and better generalization is attained compared to ANN models. The proposed model outperforms the nondeterministic models in terms of accuracy, has the flexibility to account for new modeling parameters, is easier to use as it does not require a model for propagation environment, is resistant to data collection inaccuracies and uncertain environmental information, has excellent generalization capability, and features a knowledge-based implementation that alleviates the training process. This work will facilitate network planning and propagation prediction in complex scenarios

Detection of throwing in cricket using wearable sensors

One of the great controversies of the modern game of cricket is the determination of whether a bowler is using an illegal throw-like bowling action. Changes to the rules of cricket have reduced some of the confusion, yet, because of the complexities of the biomechanics of the arm it is difficult for an umpire to make a judgement on this issue. Expensive laboratory based testing has been able to quantify the action of a bowler and this testing is routinely used by cricket authorities to assess a bowling action. Detractors of the method suggest that it is unable to replicate match conditions, has long lead times for assessment and is only available to the elite. After extensive laboratory validation we present a technology and method for an in- game assessment using a wearable arm sensor for differentiating between a legal bowling action and throwing. The method uses inertial sensors on the upper and lower arm that do not impede the bowling action. Suspect deliveries, as assessed by an expert biomechanist using high speed video and motion capture reveal valid distinctive inertial signatures. The technology is an important step in the monitoring of bowling action on-field in near real-time. The technology is suitable for use in competition as well as a training tool for developing athletes.Griffith Sciences, Griffith School of EngineeringFull Tex

Signal processing for estimating energy expenditure of elite athletes using triaxial accelerometers

Fitness development of elite athletes requires an understanding of physiological factors such as athlete energy expenditure (EE). For athletes involved in football at the elite level, it is necessary to understand the energy demands during competition to develop training regimes. By identifying an appropriate EE estimator in triaxial accelerometer data, in conjunction with identifying sources of inter-athlete variance in that estimator, signal processing was developed to extract the estimator. In this system, low-power signal processing was implemented to extract both the EE estimator and other information of physiological and statistical interestGriffith Sciences, Griffith School of EngineeringFull Tex

Performance of a live multi-gateway LoRaWAN and interference measurement across indoor and outdoor localities

Little work has been reported on the magnitude and impact of interference with the performance of Internet of Things (IoT) applications operated by Long-Range Wide-Area Network (LoRaWAN) in the unlicensed 868 MHz Industrial, Scientific, and Medical (ISM) band. The propagation performance and signal activity measurement of such technologies can give many insights to effectively build long-range wireless communications in a Non-Line of Sight (NLOS) environment. In this paper, the performance of a live multi-gateway in indoor office site in Glasgow city was analysed in 26 days of traffic measurement. The indoor network performances were compared to similar performance measurements from outdoor LoRaWAN test traffic generated across Glasgow Central Business District (CBD) and elsewhere on the same LoRaWAN. The results revealed 99.95% packet transfer success on the first attempt in the indoor site compared to 95.7% at the external site. The analysis shows that interference is attributed to nearly 50 X greater LoRaWAN outdoor packet loss than indoor. The interference measurement results showed a 13.2–97.3% and 4.8–54% probability of interfering signals, respectively, in the mandatory Long-Range (LoRa) uplink and downlink channels, capable of limiting LoRa coverage in some areas

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Background Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety, reactogenicity, and immunogenicity of fourth-dose boosters against COVID-19.Methods The COV-BOOST trial is a multicentre, blinded, phase 2, randomised controlled trial of seven COVID-19 vaccines given as third-dose boosters at 18 sites in the UK. This sub-study enrolled participants who had received BNT162b2 (Pfizer-BioNTech) as their third dose in COV-BOOST and randomly assigned them (1:1) to receive a fourth dose of either BNT162b2 (30 µg in 0·30 mL; full dose) or mRNA-1273 (Moderna; 50 µg in 0·25 mL; half dose) via intramuscular injection into the upper arm. The computer-generated randomisation list was created by the study statisticians with random block sizes of two or four. Participants and all study staff not delivering the vaccines were masked to treatment allocation. The coprimary outcomes were safety and reactogenicity, and immunogenicity (antispike protein IgG titres by ELISA and cellular immune response by ELISpot). We compared immunogenicity at 28 days after the third dose versus 14 days after the fourth dose and at day 0 versus day 14 relative to the fourth dose. Safety and reactogenicity were assessed in the per-protocol population, which comprised all participants who received a fourth-dose booster regardless of their SARS-CoV-2 serostatus. Immunogenicity was primarily analysed in a modified intention-to-treat population comprising seronegative participants who had received a fourth-dose booster and had available endpoint data. This trial is registered with ISRCTN, 73765130, and is ongoing.Findings Between Jan 11 and Jan 25, 2022, 166 participants were screened, randomly assigned, and received either full-dose BNT162b2 (n=83) or half-dose mRNA-1273 (n=83) as a fourth dose. The median age of these participants was 70·1 years (IQR 51·6–77·5) and 86 (52%) of 166 participants were female and 80 (48%) were male. The median interval between the third and fourth doses was 208·5 days (IQR 203·3–214·8). Pain was the most common local solicited adverse event and fatigue was the most common systemic solicited adverse event after BNT162b2 or mRNA-1273 booster doses. None of three serious adverse events reported after a fourth dose with BNT162b2 were related to the study vaccine. In the BNT162b2 group, geometric mean anti-spike protein IgG concentration at day 28 after the third dose was 23 325 ELISA laboratory units (ELU)/mL (95% CI 20 030–27 162), which increased to 37 460 ELU/mL (31 996–43 857) at day 14 after the fourth dose, representing a significant fold change (geometric mean 1·59, 95% CI 1·41–1·78). There was a significant increase in geometric mean anti-spike protein IgG concentration from 28 days after the third dose (25 317 ELU/mL, 95% CI 20 996–30 528) to 14 days after a fourth dose of mRNA-1273 (54 936 ELU/mL, 46 826–64 452), with a geometric mean fold change of 2·19 (1·90–2·52). The fold changes in anti-spike protein IgG titres from before (day 0) to after (day 14) the fourth dose were 12·19 (95% CI 10·37–14·32) and 15·90 (12·92–19·58) in the BNT162b2 and mRNA-1273 groups, respectively. T-cell responses were also boosted after the fourth dose (eg, the fold changes for the wild-type variant from before to after the fourth dose were 7·32 [95% CI 3·24–16·54] in the BNT162b2 group and 6·22 [3·90–9·92] in the mRNA-1273 group).Interpretation Fourth-dose COVID-19 mRNA booster vaccines are well tolerated and boost cellular and humoral immunity. Peak responses after the fourth dose were similar to, and possibly better than, peak responses after the third dose